Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 12Phase 1 10Phase 1/2 4Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 9INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 1Breast Neoplasms 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Filgrastim × Clear all
NCT02805153 2016-06-20

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
215 enrolled
Breast

Breast Neoplasms

NCT01164475 2014-02-25

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Sanofi

Phase 4 Completed
61 enrolled 19 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡